Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 7—July 2003

Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance

Sue Lim*†, Darrin Bast*†, Allison McGeer*†, Joyce de Azavedo*†, and Donald E. Low*†Comments to Author 
Author affiliations: *Toronto Medical Laboratories/Mount Sinai Hospital, Toronto, Ontario, Canada; †University of Toronto, Toronto, Ontario, Canada

Main Article

Table 4

Characterization of Streptococcus pneumoniae isolates with levofloxacin MIC 4 μg/mLa

Isolate no. Amino acid substitution
Change in MIC
with inhibition of efflux
In ParC In GyrA
1 Ser79→Phe None 8-fold
2 Ser79→Phe None No effect
3 Asp78→Asn Ser81→Phe No effect
4 Ala115→Pro Ser81→Phe No effect
5 Ser79→Phe None No effect
6 Ser79→Phe None No effect
7 None None 4-fold
8 Ser79→Phe Ser81→Phe No effect

aparE and gyrB sequencing was performed on all isolates, but no mutations were found in the quinolone-resistance–determining region.

Main Article

Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.